Synairgen plc (SYGGF)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Apr 14, 2026, 4:00 PM EST
Market Cap110.27K -99.7%
Revenue (ttm)n/a
Net Income-8.53M
EPS-0.04
Shares Out1.10B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,000
Average Volume3,583
Open0.0141
Previous Close0.0001
Day's Range0.0001 - 0.0141
52-Week Rangen/a
Beta5.24
RSI32.83
Earnings DateMay 28, 2026

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 34
Stock Exchange OTCMKTS
Ticker Symbol SYGGF
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements